Six or more FDA PDUFA target dates are expected in mid-to-late 2026 for oncology assets spanning antibody-drug conjugates, checkpoint inhibitors, and precision small molecules — making the next 18 months among the most catalyst-dense periods in recent biotech history.
ADC combinations lead the near-term calendar. Ifinatamab Deruxtecan and Ziihera are both approaching PDUFA dates, extending the ADC franchise beyond its current approved indications. CR-001 ADC combinations represent a further pipeline inflection extending into 2027. Checkpoint inhibitor Tecentriq and PI3K inhibitor Gedatolisib round out the binary event slate.
Alongside regulatory timelines, clinical data is sharpening the investment case. AbbVie presented EHA 2026 data showing venetoclax plus obinutuzumab delivered a median time to next treatment of approximately eight years in previously untreated chronic lymphocytic leukemia — a durability signal that underscores the value of combination regimens in hematologic malignancies.1
In bispecifics, epcoritamab is advancing in follicular lymphoma. Selinexor, an exportin-1 inhibitor, is being evaluated in the SENTRY trial, adding a mechanistically distinct asset to the oncology binary event calendar.
The longer-horizon catalyst attracting attention is Century Therapeutics' CNTY-813, an iPSC-derived cell therapy targeting type 1 diabetes. T1D affects approximately nine million people worldwide.2 Current islet cell transplantation achieves insulin independence in roughly 70% of patients at one year, but requires chronic systemic immunosuppression.2 CNTY-813 preclinical data presented at ADA 2026 demonstrated durable glucose control and immune evasion under alloimmune pressure — a differentiated profile if validated clinically.
The ASCEND proof-of-concept readout is expected in Q1 2027, extending the catalyst window beyond the current PDUFA cluster and offering investors a staged entry into next-generation modalities.
For biotech investors, the setup is structurally familiar: concentrated binary events, asymmetric payoffs, and pipeline diversification across modalities that reduce single-asset concentration risk. ADC combinations, bispecifics, iPSC cell therapies, and exportin inhibitors each carry distinct mechanisms — and distinct failure modes. Approval of any single asset will not validate the others.
The 2026–2027 regulatory calendar presents the most concentrated oncology binary environment since the immuno-oncology approval wave of the mid-2010s. Portfolio positioning around PDUFA dates — rather than chasing post-approval moves — is where the asymmetry sits.3
